Skip to main content
Equibles
ICU logo

ICU · SeaStar Medical Holding Corp · Metrics

Track ICU — free

Use ICU with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ICU.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.50 +0.09 (+3.73%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company believes that these conditions raise substantial doubt about its ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$10.62M
Shares
4.41M
Volume · Oct 26 102.69K Avg daily vol (3M) 122.05K

ICU metrics

63 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.47
Market cap
$10.62M

Price action

20 metrics
Price change (1W)
-16.9%
Price change (30D)
-29.1%
Price change (3M)
-35.7%
Price change (6M)
-41.6%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
113.6%
Annualized volatility (3M)
114.9%
Beta
1.1
RSI (14D)
37.0
Price vs SMA 50
-26.6%
Price vs SMA 200
-27.6%
Avg volume (3M)
121,680
Relative volume
2.8
Average dollar volume
$415,894

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
4.41M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
6.2×
reciprocal yield 16.1%
P / book
2.5
reciprocal yield 40.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-128.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-12

Profitability

9 metrics
Gross margin
92.6%
Operating margin
-816.8%
Trailing 12 months
Net margin
-795.5%
Gross profit (TTM)
$1.59M
Operating profit (TTM)
−$13.99M
Net income (TTM)
−$13.63M
Trailing 12 months
Diluted EPS (TTM)
$-14.90
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$2.71

Growth

11 metrics
Revenue growth YoY
+82.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.71M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+259.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-317.2%
Return on assets
-157.6%
Debt / equity
0.0
Current ratio
1.9
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.9
Interest coverage
-559.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$2.08M
Latest balance sheet
Cash & equivalents
$6.30M
Total assets
$8.65M
Total debt
$134,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$13.69M
Capital expenditures (TTM)
—
R&D (TTM)
$8.91M
SG&A (TTM)
—
Stock compensation (TTM)
$352,000
R&D / revenue
520.4%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
33
13F filer change QoQ
+6
Institutional ownership
30.0%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
0.4%
Private-fund adviser ownership
0.0%
Active holders' share change QoQ
+56.6%
Holder tenure
2.9
Price vs estimated holder cost
-12.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.6%

Short interest

3 metrics
Short interest
4.2%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
46 / 100

Insider activity

2 metrics
Net insider buying (90D)
$2,452
Insider-sentiment score
75 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1831868 CUSIP 81256L302 13F (30d) 2 filings 2 filers Visit website Investor relations